Saurabh S Dani, MD, MSc
@saurabhsdani
Premature CAD Cardiologist, Outcomes research, Health Economics, Associate Prof @TuftsUniversity @UmassChan @LSEHealthpolicy Program Director @LaheyCardiology
ID: 254841774
20-02-2011 03:41:46
2,2K Tweet
4,4K Followers
1,1K Following
Incredibly proud of our fellow Rushin Patel MD for leading the crucial study of SGLT-2i and GLP1RA incremental benefits in HFpEF! Kudos to the dedicated mentors and fantastic team Sarju Ganatra, MD, FACC Saurabh S Dani, MD, MSc Javed Butler Gregg Fonarow MD Dr. Deepak L. Bhatt
#cardiology #cardioX JACC Journals
New #ESCGuidelines on #Afib 2024 The 🆕 AF-CARE pathway 💡Comorbodity and risk factor management 💡Avoid stroke 💡Reduce symptoms by rate and rhythm control 💡Evaluation and dynamic reassessment #ESCCongress European Society of Cardiology
GLP-1 RA reduces CV events & CKD progression, independent of SGLT2i - supporting combination therapy with both agents to improve cardio-renal outcomes in type 2 diabetes Our most comprehensive analysis yet, #simpub in Circulation for #ESCCongress ahajournals.org/doi/abs/10.116…
2024 #ESCGuidelines for the management of elevated blood pressure and #hypertension: Developed by the task force on the management of elevated #BP and hypertension of European Society of Cardiology and endorsed by European Society of Endocrinology (ESE) and European Stroke Org. academic.oup.com/eurheartj/adva… #ESCCongress European Society of Cardiology Journals
Colchicine improves outcomes in coronary disease, but will it in heart failure? Discover more in #EHJ: academic.oup.com/eurheartj/adva… #ESCCongress #inflammation #colchicine #CVD #outcome European Society of Cardiology European Society of Cardiology Journals
Multi-Institute study in JACC Journals led by Lahey Hospital investigators shows incremental benefits of #GLP1RA in addition to #SGLT2i for those with #heartfailure #HFpEF #obesity #diabetes sciencedirect.com/science/articl…
nature.com/articles/s4159… Among nearly 19K patients across 3 high risk populations--FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF--finerenone reduced the risk of all-cause mortality by 9%. (HR 0.91; 95% CI 0.84-0.99; P = 0.027) Muthu Vaduganathan
Recalibration of risk score of cardiovascular disease for the Asia-Pacific population. Read more about the SCORE2 Asia-Pacific model in EHJ. doi.org/10.1093/eurhea… #CVD #ESCCongress #cardiotwitter European Society of Cardiology Journals European Society of Cardiology
Would love to see the threshold LDL mg/years (total plaque burden) for South Asian population for plaque rupture. Too long to wait for 5000 LDL-years! #Premature CAD Sarju Ganatra, MD, FACC Jaideep Alka Kanaya Priyanka Satish Anandita Agarwala Kulkarni, MD FACC Khurram Nasir Salim Virani Dinesh Kalra, MD Romit Bhattacharya
Wow! The popularity of #Jeopardy at the World Congresses is a testament to the tremendous efforts poured in by American College of Cardiology at the regional and the national levels #ACC conferences! More responsibilities for the next generation to take the show to the higher highs at #ACC25
Saurabh S Dani, MD, MSc Sarju Ganatra, MD, FACC Jaideep Alka Kanaya Priyanka Satish Anandita Agarwala Kulkarni, MD FACC Salim Virani Dinesh Kalra, MD Romit Bhattacharya Athero very heterogeneous and complicated process and trying to simplify as an easy concept as "LDL life years" is just not good science or policy Huge differences across the LDL years spectrum where folks develop at a lower threshold and never with highest lifetime exposure.
Superb work by Lahey Cardiology stellar fellow Rushin Patel MD and fantastic collaborators led by Sarju Ganatra, MD, FACC !